| |
Wednesday, January 11, 2023 | 2:00pm ET Recent advances in natural language processing (NLP) caused an explosion of practical use cases that have now become viable. This webinar for healthcare & life sciences leaders surveys common NLP applications that are being widely deployed, including real world data extraction from pathology & radiology reports, patient risk adjustment & HCC coding, and more. Register now.
|
|
Today's Big NewsJan 3, 2023 |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT UGTs are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Hear Dr. Brian Ogilvie discuss case studies and strategies to address non-CYP related metabolism questions in your drug’s safety assessment. Register now.
|
|
| By Paige Minemyer Just ahead of the year-end deadline, President Joe Biden signed into law a massive $1.7 trillion spending package that includes a slew of healthcare policy priorities. |
|
|
|
By Max Bayer Merck KGaA is continuing its recent run of dealmaking, handing over an IL-12-targeting cancer med to PDS Biotech in a deal worth more than $120 million. The med is being tested as part of a triple combo therapy that also includes PDS Biotech's lead immunotherapy asset. |
By Kevin Dunleavy Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. In 2022, however, fewer drugs were approved than was typical in recent years. Is this the result of the FDA becoming gun-shy after its much-criticized sanction of Biogen's Alzheimer's disease treatment, Aduhelm, in 2021? Or was 2022 just a cyclical blip on the approval landscape? |
By Andrea Park Right after a major win for Apple in its patent dispute with fellow wearable device maker AliveCor, the tech giant has hit a roadblock. |
|
Tuesday, January 24, 2023 | 11am ET / 8am PT Your CRO is a finalist in a project bid and clinical supplies are one of the aspects that you will manage on behalf of the client via a partner. Register now.
|
|
By Annalee Armstrong A scathing congressional report has detailed communications described as "inappropriate" and "atypical" between Biogen and the FDA regarding the approval of Alzheimer’s disease drug Aduhelm plus the decision-making behind the pricing and marketing of the now-benched medicine. |
By Annalee Armstrong Gilead plans to work with EVOQ Therapeutics to hopefully bring to mind new treatments for autoimmune disorders in a deal worth up to $658.5 million. |
By Andrea Park New year, new CEO. That’s the 2023 mantra for ReCor Medical, which kicked off the year with the appointment of a new leader. |
By Dave Muoio First announced in October, the deal brings Tulane Medical Center, Lakeview Regional Medical Center and Tulane Lakeside Hospital under the nonprofit system's belt. The purchase had been opposed by a major nurses' union. |
By Nick Paul Taylor Valneva’s plans to establish its COVID-19 vaccine as a booster to Pfizer and BioNTech’s Comirnaty have taken a blow, with a clinical trial of the shot eliciting “only a marginally increased neutralizing antibody response.” |
By Angus Liu Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. The lawsuit centered on an agreement Novartis and Endo's Par signed in 2011 that allegedly pushed back the launch of a copycat to Novartis' Exforge. |
By Andrea Park The growing list of medtech CEO switch-ups is beginning to resemble a game of musical chairs—and one experienced leader just found a new seat. |
By Paige Minemyer Sign-ups on the Affordable Care Act's exchanges continue at a record pace, according to new data from the Biden administration. |
By Annalee Armstrong Seeds from Mayo Clinic’s cell and gene therapy accelerator Mayflower Bioventures have taken flight in a new biotech called Primera Therapeutics, which launches today with a blossoming $750 million partnership to work on therapies for mitochondrial diseases. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about this year's class of digital health companies that crossed the $1 billion valuation despite an overall funding slowdown. We also discuss how best to leverage population health management to improve how care is delivered and make it more holistic. |
|
|---|
|
|
|
Wednesday, January 25, 2023 | 1:00pm ET In this webinar, you’ll learn about a case study pursued in collaboration with Geneos Therapeutics and Personalis to utilize a tumor-informed ctDNA assay to retrospectively analyze clinical response to a class of personalized immunotherapies developed against tumor-specific neoantigens in advanced hepatocellular cancer (HCC) patients. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
